- Previous Close
333.50 - Open
325.00 - Bid --
- Ask --
- Day's Range
309.00 - 325.00 - 52 Week Range
179.00 - 375.50 - Volume
539 - Avg. Volume
1,878 - Market Cap (intraday)
3.97B - Beta (5Y Monthly) 1.12
- PE Ratio (TTM)
1.74 - EPS (TTM)
1.83 - Earnings Date May 21, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates through two segments, Ypsomed Delivery Systems and Ypsomed Diabetes Care. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
www.ypsomed.com2,600
Full Time Employees
March 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: 0QLQ.L
View MorePerformance Overview: 0QLQ.L
Trailing total returns as of 4/7/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0QLQ.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0QLQ.L
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
12.06%
Return on Assets (ttm)
5.73%
Return on Equity (ttm)
12.44%
Revenue (ttm)
617.07M
Net Income Avi to Common (ttm)
74.39M
Diluted EPS (ttm)
1.83
Balance Sheet and Cash Flow
Total Cash (mrq)
52.31M
Total Debt/Equity (mrq)
52.29%
Levered Free Cash Flow (ttm)
-117.25M